Analytical (=Technical) validation
The top of the image shows the tail of a preceding biomarker validity table, including:
- text about performance characteristics and a body of evidence that elucidates physiologic, toxicologic, pharmacologic, or clinical significance of test results;
- text about widespread agreement in the medical or scientific community;
- cross-validation/replication at different sites;
- examples including
EGFR MUTATION, k-ras mutation.
Biomarker development process
| discovery | Method development | Validation studies | Cross-validation consortium |
|---|---|---|---|
| pre-validation; exploratory method validation; advanced method validation; in-study method validation |
Analytical (=Technical) validation
Table Structure
Visible column headers:
| parameter | definition | Method | Affected by | Acceptance criteria |
|---|
Upper Rows
| parameter | conservative transcription |
|---|---|
| Population range | Affected by: Healthy vs Disease status. Other cells are blank or not reliably readable. |
| Assay range | Affected by: assay working range dependent on the antibody reagents used. Acceptance criteria appears to say 80-120% of test concentration ?. |
| Standard curve | Row visible, content not reliably filled in this crop. |
Sensitivity
| subtopic | definition / notes | method | affected by | acceptance criteria / examples |
|---|---|---|---|---|
| LLOQ | LLOQ: LLOQ is considered as the minimum concentration of analytes which can be determined with a precision (CV%) of 20%. | Estimated by signal-to-noise ratio of 10:1, or 10 x sd / Slope according to OCR; formula needs manual check. | LLOQ is a term used in bioanalysis and it is equivalent to LOQ. | Acceptance text appears: At LLOQ, CV is between 20-25%. Small table has ASC (ng/mL) values 22.2, 7.41, 2.5, 0.82 and CV (%) values 7.0, 8.5, 9.0, 22.3; note says 0.82 is LLOQ. |
| LOD (limit of detection) | the lowest analyte concentration that can be distinguished from the assay background (blank). | Estimated by signal-to-noise ratio of 3:1, or 3.3 x Standard Deviation / Slope with suitable accuracy and precision. A displayed formula for LOD/LLD is present but should be checked from the image before reuse. | Embedded figure: Analytical Method Validation LOD and LOQ; surrounding text says 95% of values will exceed the previously defined LoB, and only 5% of low concentration samples will produce values below the LoB. | Korean note beside LLOQ/LOD should be manually verified. |
| signal-to-background ratio (S/B) | Formula displayed as S/B = mean signal / mean background in the image/OCR. | |||
| signal-to-noise ratio (S/N) | Formula displayed as S/N = (mean signal - mean background) / standard deviation of background in the image/OCR. | Text says signal-to-noise ratio is a better metric than signal-to-background because it accounts for variation in the background. | ||
| Z’-factor | A Molecular Devices URL is visible: https://www.moleculardevices.com/en/assets/app-note/br/better-metrics-for-comparing-instruments-and-assays#gref or similar. | URL suffix requires manual check. | ||
| Detection range | Notes include: the lowest standard to the highest standard, dynamic range, and LLOD-ULOD; Korean notes discuss sample type/standard testing. | Korean text needs manual verification. |
Specificity / Selectivity / Accuracy
| parameter | conservative transcription |
|---|---|
| Specificity | Method cell shows IC50. Affected-by text: the ability of the assay to clearly distinguish the analyte of interest from components that can alter assay results. |
| Selectivity | Affected-by text: the degree to which unrelated matrix components cause analytic interference. |
| Accuracy (=trueness) | Left definition: closeness between the true value & the experimental value; Korean note indicates values must match. |
Accuracy: Spike & recovery
| field | conservative transcription |
|---|---|
| title | Spike & recovery |
| notes | Korean notes indicate checking whether a value matches at one point and whether there is matrix interference; exact wording should be manually verified. |
| method | Spike and recovery: a known amount of recombinant protein is spiked (added) into a sample and run in the ELISA. The resulting concentration/recovery of the spiked material demonstrates whether the expected value can be measured accurately. |
| example | Example says if serum is spiked with known 1000 pg/ml recombinant human IL-2 but the spiked sample measures at 80 pg/ml, a factor in the serum sample may inhibit detection of IL-2 by antibodies used in the assay. |
| calculation note | Korean/English note: next result value (recovery) should be 100%; %Recovery = (3-1)/2; 3 is spike + analyte / spiked sample / spike + endogenous; 1 is analyte only / unspiked sample / endogenous only; 2 is spike only / spiked blank; sample diluent = blank. |
| acceptance criteria | 80-120% recovery. |
Accuracy: Dilution linearity
| field | conservative transcription |
|---|---|
| title | Dilution linearity |
| definition | Ability, within a given range, to obtain test results directly proportional to the concentration/amount of analyte in the sample. |
| notes | Korean notes indicate values should match proportionally and relate to matrix interference; exact wording should be manually verified. |
| method | A spiked or unspiked sample is serial-diluted, such as 1:2, 1:4, and 1:8. If a sample does not exhibit linear dilution, this indicates a matrix component is interfering with accurate detection of a specific analyte at a given dilution. |
| MRD | MRD: the minimum magnitude of dilution to which a sample must be subjected to optimize accuracy and precision in an assay run with a specified standard and sample diluent. Another cell describes MRD as the dilution factor where change in concentration from previous dilution starts to be linear/constant and is between 80-120% of expected sample recovery. |
| example / figures | Example text and figures are partially visible. It discusses MRD established by testing neat unspiked sera and unspiked sera diluted 1/10 and 1/100 in dilution buffer from 6 donors, with background caused by non-specific antibody binding. Figure labels and citation details need manual verification. |
| acceptance / reference | Acceptance criteria area includes linear regression, r2 > 0.98, 20210825 Kamiguchi, and MRD of 4 is acceptable; text says below is a good example and references a %dilution linearity calculator. Exact citation/labels should be checked. |
Parallelism
| field | conservative transcription |
|---|---|
| title | Parallelism |
| definition | Calibrators of known concentrations to samples of unknown concentration; sample-dilution response curve is parallel to the standard-calibrator response curve; proportionality between endogenous biomarker and recombinant calibrator. |
| notes | Margin note says spike-recovery may be more important than parallelism. |
| method/interpretation | Parallelism indicates similar binding properties for the capture antibody to the endogenous biomarker and calibrator. |
| affected-by text | Two major factors that contribute to nonparallelism are: difference between immunoaffinity characteristics of calibrator reference material and unknown analyte; and matrix effects/variance among calibration curve matrix and study population matrix. |
| figures | Small plots/figures are visible, including an Eg: anderson 2021 note and a plot mentioning NLRP3 concentration; labels are not reliable enough for exact transcription. |
Precision / Repeatability
The bottom of the image begins the next section:
| parameter | conservative transcription |
|---|---|
| Precision | Left edge shows a continuation into Precision. |
| Repeatability | the closeness of agreement among results...; acceptance criteria visible at far right: CV (Coefficient of variation): 20%. The row continues beyond this crop/photo. |
Uncertain Spans
- The page title/navigation in the prior fallback was corrected from
Genetic prevalencetoAnalytical (=Technical) validationbased on the image and status/nav evidence. - Exact dense table values, formulas, graph labels, figure captions, citations, URLs, and Korean notes remain uncertain unless they are explicitly transcribed above as conservative text.
- The small LLOQ table appears to contain
ASC (ng/mL)andCV (%)values, but the header may beASC/A5C/similar; verify before using. - The LOD/LLD formula, Molecular Devices URL, MRD example text, donor labels, and NLRP3/Anderson figure labels should be checked against higher-resolution crops or adjacent photos.
- Korean annotations are only partially captured; preserve image evidence and manually verify wording before using in final KB.